期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

高效抗逆转录病毒治疗与抗结核治疗的联合应用策略

下载PDF
导出
摘要 结核分枝杆菌感染是人类免疫缺陷病毒感染／艾滋病（HIV／AIDS）患者最常见的机会感染之一，也是AIDS患者死亡的重要原因，证据表明对HIV／AIDS合并结核病（TB）患者，联合应用高效抗反转录病毒治疗（HAART）与抗结核（ATB）治疗能改善预后。
作者 卢水华
机构地区 上海市公共卫生临床中心 复旦大学附属公共卫生临床中心呼吸科
出处 《临床肺科杂志》 2011年第5期743-745,共3页 Journal of Clinical Pulmonary Medicine
关键词 抗结核治疗 高效抗逆转录病毒治疗 联合应用 人类免疫缺陷病毒感染 高效抗反转录病毒治疗 AIDS患者 结核分枝杆菌感染 HIV/AIDS
分类号 R512.91 [医药卫生—内科学] R52 [医药卫生—内科学]
  • 相关文献

参考文献15

  • 1Velasco M, Castilla V, Sanz J, el al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tu- berculosis[J]. J Acquit Immune Defic Syndr, 2009,50(2):148-52.
  • 2World Health,Organiztion. Tuberculosis care with TB-HIV co-man- agement integrated management of adolescent and adult illness[ J]. Geneva : WHO Press, 2007:28 - 35.
  • 3Harries A, Maher D, Graham S. TB/HIV: a clinical manual. 2rd edition [ J ]. Geneva: World Health organization; 2004. WHO/ HTM/TB/2004, 329 - 334.
  • 4HavlirDV, Getahun H, Sanne 1, et al. Opportunities and challen- ges for HIV care in overlapping HIV and TB epidemics[ J ]. JAMA, 2008, 300(4) :423 -430.
  • 5Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents; Recommendations for HIV-prevalent and ned set- ting[ J]. Geneva, World Health Organization, 2007 ( WHO/HTM/ TB/2007. 379; WHO/HIV/2007.01.
  • 6Battegay M, Fehr J, Fliickiger U, et al. Antiretroviral therapy of late presenters with advanced HIV disease[J]. J Antimicrob. Che- mother, 2008, 62(7) : 41 -44.
  • 7Bartlett JG, Lane HC, Pau AK, et al. Guidelines for the use of an- tiretro~iral agents in HIV-infected adults and adolescents [ J]. [ EB/OL ],2008 - 09 - 30.
  • 8李太生.国内外艾滋病抗病毒治疗研究进展[J].传染病信息,2008,21(6):324-326. 被引量：24
  • 9Kwara A, Ranigan TP, Carter EJ. Highly active antiretroviral thera- py(HAART) in adults with tuberculosis:current status [ J ]. Int J Tuberc Lung Dis,2005,9:248 -257.
  • 10沈银忠.艾滋病合并结核病患者的抗结核治疗[J].上海医药,2009,30(1):8-11. 被引量：22

二级参考文献26

  • 1Zhang F,Dou Z,Yu L,et ol. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China[J]. Clin Infect Dis, 2008,47(6):825- 833.
  • 2UNAIDS. AIDS epidemic Update 2007 [EB/OL]. [2008-09- 30]. http://www.unaids.org/wad2007/report.html.
  • 3Ho DD, Neumann AU, Perelson AS,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [J]. Nature, 1995,373(6510):123-126.
  • 4Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection[J]. Nature, 1995, 373(6510):117-122.
  • 5Staszewski S, Morales-Ramirez J,Tashima KT,et al. Efavirenz plus zidovudine and lamivudine,efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treat- ment of HIV-1 infection in adults. Study 006 Team[J]. N Engl J Med, 1999,341(25):1865-1873.
  • 6Gallant JE, Staszewski S, Pozniak AL, et ol. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial[J]. JAMA, 2004,292(2):191-201.
  • 7Steigbigel R, Kumar P, Eron J, et al. Results from BENCH-MRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV- 1 integrase inhibitor, in patients with triple-class resistant virus[C/OL]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, February 25-28,2007. [2008-09-30]. http://www.retro- conference.org/2007/Abstracts/30688.htm.
  • 8Anton P, Morales-Ramirez J, Mohapi L, et al. 48-week primary analysis of trial TMC278-C204:TMC278 demonstrates potent and sustained efficacy in ART-naive patients[C/OL]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles,USA,February 25-28,2007.[2008-09- 30].http://www.retroconference.org/2007 /Abstracts/30659.htm.
  • 9Valdez-Madruga J, Berger DS, McMurchie M, et al. Comparison of 48-week efficacy and safety of darunavir/ritonavir (DRV/r) with lopinavir/ritonavir (LPV/r) in LPV/r-naive, treatment-experienced patients : a randomised, controlled phase III trial (TITAN) [C/OL].4th International AIDS Soci- ety Conference on HIV Pathogenesis, Treatment and Prevention, Sydney,Australia, July 22--25,2007. [2008-09-30]. http://www.natap.org/2OO7 /IAS/IAS_16.htm.
  • 10Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel[J]. JAMA, 2006,296(7): 827-843.

共引文献43

临床肺科杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部